Noninvasive prenatal screening (NIPT basic), risk diagnosis of Down, Edwards and Patau syndromes in the fetus.

Non-Invasive Prenatal Testing (NIPT)

NIPT (noninvasive prenatal screening) is the analysis of free—circulating fetal DNA for the purpose of screening fetal chromosome aneuploidy:

Trisomy 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Patau syndrome).

Advantages:

·High-quality genetic research with risk assessment. Genome-wide sequencing of low-coverage free-circulating DNA by new generation sequencing (NGS)

·More than 10 million completed tests worldwide.

··The test results are subject to three-stage verification: the results obtained using automated software are checked by a laboratory expert; anonymized data is checked by bioinformatics experts at the international company BGI, the world leader in the field of genetics and developer of the NIFTY test; the final interpretation of the results is carried out by a certified geneticist.

A noninvasive prenatal test for chromosomal abnormalities is more reliable and safer than other fetal aneuploidy tests.:

·Reliability above 99% (accuracy/sensitivity)

·100% safe. Non-invasive test is safe for mom and baby's health

·Can be carried out from 10 weeks

·Simplicity – 10 ml of venous blood is enough

·Reliability